NANO Nanobiotix SA

NANOBIOTIX to Present at the 5th Annual Evercore ISI HealthCONx Conference

NANOBIOTIX to Present at the 5th Annual Evercore ISI HealthCONx Conference

PARIS and CAMBRIDGE, Mass., Nov. 15, 2022 (GLOBE NEWSWIRE) -- (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that Laurent Levy, co-founder and chairman of the executive board, and Bart Van Rhijn, chief financial officer, will participate in a virtual fireside chat at the 5th annual Evercore ISI HealthCONx Conference on Thursday, December 1, 2022, at 9:15 AM ET / 3:15 PM CET.

The fireside chat will be webcast live from the of the Investors section of the Company’s website. A replay of the webcast will be archived and available for 90 days following the event.

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The company is leveraging its proprietary nanoparticle platform, including its lead product candidate, radiotherapy activated NBTXR3, to develop a pipeline of therapeutic options designed to enhance local and systemic control of solid tumors with an initial focus on the treatment of head and neck cancers.

For more information about Nanobiotix, visit us at or follow us on and .

Contacts

Nanobiotix


Communications Department

Brandon Owens

VP, Communications

+1 (617) 852-4835







Investor Relations Department

Kate McNeil

SVP, Investor Relations

+1 (609) 678-7388





Media Relations


FR – Ulysse Communication

Pierre-Louis Germain

+ 33 (0) 6 64 79 97 51





Global – LifeSci Advisors

Ligia Vela-Reid

+44 (0) 7413825310

 



EN
15/11/2022

Underlying

NANONanobiotix SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nanobiotix SA

 PRESS RELEASE
Free
NANO NANOBIOTIX SA

NANOBIOTIX to Participate in Investor Conferences in March

NANOBIOTIX to Participate in Investor Conferences in March PARIS and CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in these upcoming conferences in March: TD Cowen's Health Care ConferenceDate: Wednesday, March 4, 2026Location: Boston, MATime of the fireside chat: 11:10am ET / 5:10pm CETPresenters: Laurent Levy,...

February 25, 2026 1 EN
 PRESS RELEASE
Free
NANO NANOBIOTIX SA

NANOBIOTIX participera à plusieurs conférences investisseurs en mars

NANOBIOTIX participera à plusieurs conférences investisseurs en mars PARIS et CAMBRIDGE, Mass., 25 févr. 2026 (GLOBE NEWSWIRE) -- (Euronext : NANO –– NASDAQ : NBTX – la « Société »), société française de biotechnologie en phase de développement clinique avancé, pionnière des approches fondées sur les nanoparticules pour élargir les possibilités de traitement des patients atteints de cancer ou d’autres maladies, annonce aujourd’hui qu’elle participera aux conférences suivantes en mars : TD Cowen's Health Care ConferenceDate : mercredi 4 mars 2026Lieu : Boston, MA (États-Unis)Horaire de l...

February 25, 2026 1 EN
Free Trial
NANO NANOBIOTIX SA

Nanobiotix: 1 director

A director at Nanobiotix bought 1,100 shares at 26.618USD and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...

02/19/26 February 19, 2026 1 EN
 PRESS RELEASE
Free
NANO NANOBIOTIX SA

Voting Rights and Shares Capital of the Company

Voting Rights and Shares Capital of the Company In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: DateNumber of Shares OutstandingTotal number of voting rightsTotal voting rights, theoretical1Total voting rights, exercisable2January 31, 202648,450,35850,153,46050,131,342 About NANOBIOTI...

February 17, 2026 1 EN
 PRESS RELEASE
Free
NANO NANOBIOTIX SA

Information mensuelle relative au nombre total de droits de vote et d...

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 17 févr. 2026 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Paris / NasdaqEuronext Compartiment : B Code ISIN : FR0011341205Nasdaq : NBTXBloomberg : NANO:FPReuters : NANO.PASite web : DateNombre total d’actions composant le capital socialNombre total de droits de voteTotal théorique1Total exerçable231 janvier 202648 450 35850 153 46050 131 342 À pr...

February 17, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch